PepGen (PEPG) Total Current Liabilities (2021 - 2026)
PepGen (PEPG) reported Total Current Liabilities of $9.0 million for Q1 2026, down 56.13% on a YoY basis from $20.4 million in Q1 2025, and down 29.12% sequentially from $12.6 million in Q4 2025.
PepGen (PEPG) Total Current Liabilities (2021 - 2026) Analysis & Trends
PepGen (PEPG) has 6 years of Total Current Liabilities data on file, last reported at $9.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 56.13% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $9.0 million (down 56.13% YoY), and the FY2025 full-year result was $12.6 million, down 24.26% from the prior year.
- Total Current Liabilities fell to $9.0 million in Q1 2026, from $12.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $22.1 million in Q2 2024 to a low of $9.0 million in Q1 2026.
- A 5-year average of $16.6 million and a median of $16.8 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 82.42% in 2022 and tumbled 56.13% in 2026, its largest moves.
- Tracing PEPG's Total Current Liabilities over 5 years: stood at $18.8 million in 2022, then retreated by 6.89% to $17.5 million in 2023, then dropped by 4.76% to $16.7 million in 2024, then retreated by 24.26% to $12.6 million in 2025, then retreated by 29.12% to $9.0 million in 2026.
- Business Quant data shows PEPG's Total Current Liabilities at $9.0 million in Q1 2026, $12.6 million in Q4 2025, and $12.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 289.60 Mn |
| 10 | PepGen | 133.00 Mn | 133.00 Mn | - | 8.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.96 Mn |
| Dec 31, 2025 | 12.65 Mn |
| Sep 30, 2025 | 12.64 Mn |
| Jun 30, 2025 | 16.36 Mn |
| Mar 31, 2025 | 20.43 Mn |
| Dec 31, 2024 | 16.70 Mn |
| Sep 30, 2024 | 16.81 Mn |
| Jun 30, 2024 | 22.11 Mn |
| Mar 31, 2024 | 11.26 Mn |
| Dec 31, 2023 | 17.53 Mn |
| Sep 30, 2023 | 20.96 Mn |
| Jun 30, 2023 | 16.94 Mn |
| Mar 31, 2023 | 18.03 Mn |
| Dec 31, 2022 | 18.83 Mn |
| Sep 30, 2022 | 15.52 Mn |
| Jun 30, 2022 | 20.58 Mn |
| Mar 31, 2022 | 16.12 Mn |
| Dec 31, 2021 | 10.32 Mn |